Clinical Trials Logo

Metastases clinical trials

View clinical trials related to Metastases.

Filter by:

NCT ID: NCT06356779 Recruiting - Surgery Clinical Trials

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

OLIGO-DK
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations. The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.

NCT ID: NCT05261113 Completed - Surgery Clinical Trials

CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases

Start date: January 1, 2017
Phase:
Study type: Observational

Contrast-enhanced intraoperative ultrasound (CE-IOUS) plays an increasingly important role in the surgical therapy planning of primary liver lesions as well as liver metastases. The present study was designed to evaluate the significance of CE-IOUS by specificity and sensitivity and particularly the impact it exerts on the surgical strategy. A secondary aim was assessing the outcome relevance of surgeries influenced by CE-IOUS.

NCT ID: NCT05195710 Recruiting - Metastases Clinical Trials

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Start date: November 16, 2022
Phase: Phase 1
Study type: Interventional

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.

NCT ID: NCT05136768 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

LM-HNSCC
Start date: December 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of combination of Sintilimab and SBRT on the basis of platinum-containing chemotherapy as the first-line treatment of limited metastatic head and neck squamous cell carcinoma (LM-HNSCC).

NCT ID: NCT04987086 Recruiting - Renal Cancer Clinical Trials

68Ga-PSMA PET in the Renal Cell Carcinoma

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma

NCT ID: NCT04967001 Recruiting - Prostatic Neoplasms Clinical Trials

68Ga-PSMA PET in the Prostate Cancer

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Efficacy of 68Ga PSMA PET / CT in the diagnosis of lymph node metastasis in patients with prostate cancer: a single center prospective randomized controlled trial. To identify and compare the diagnostic efficacy of 68Ga-PSMA PET/CT and mpMRI for lymph nodes in patients with newly diagnosed prostate cancer.

NCT ID: NCT04825470 Not yet recruiting - Liver Cancer Clinical Trials

Liver Transplantation for Unresectable GIST Liver Metastases

TRANSGIST
Start date: May 2022
Phase: N/A
Study type: Interventional

Liver Transplantation for Unresectable GIST Liver Metastases

NCT ID: NCT04066322 Recruiting - Surgery Clinical Trials

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

RMPanNET
Start date: August 25, 2019
Phase:
Study type: Observational [Patient Registry]

This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.

NCT ID: NCT03977818 Completed - Sarcoma Clinical Trials

METASARC: Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa

METASARC
Start date: January 1, 1990
Phase:
Study type: Observational

Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals. The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group will be analyzed with a focus on : number/frequency of systemic treatments per patient, number/frequency of patients with locoregional treatment of the metastasis, number/frequency of patients with chemotherapy, number/frequency of patients with an off-label drug. Outcome (time-to-next treatment [TNT] and overall survival [OS]) will be reported according to histological subtype, as well as the association between TNT and OS. Prognostic factors of OS will be investigated.

NCT ID: NCT02452294 Recruiting - Malignant Melanoma Clinical Trials

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

BUMPER
Start date: July 2015
Phase: Phase 2
Study type: Interventional

The study will enrol adult female and male patients with BRAF wild-type melanoma and brain metastases who are not eligible for surgery or radiosurgery and failed prior therapy with ipilimumab, and patients with BRAF V600 mutation-positive melanoma and brain metastases who are not eligible for surgery or radiosurgery and who failed prior therapy with a BRAF inhibitor.